Portal de Periódicos da CAPES

Racial and Ethnic Disparities in Clinical Trial Recruitment in the U.S.

2021; Elsevier BV; Volume: 61; Issue: 5 Linguagem: Inglês

10.1016/j.amepre.2021.05.007

1873-2607

Young‐Rock Hong, Amir Alishahi Tabriz, Kea Turner,

Health Systems, Economic Evaluations, Quality of Life

Diversity in research participation is essential for ensuring that new interventions benefit all populations. In the U.S., the under-representation of Black and Hispanic Americans in clinical research has persisted over time and poses a significant obstacle to developing and implementing interventions to improve population health. 1 Loree JM Anand S Dasari A et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019; 5e191870https://doi.org/10.1001/jamaoncol.2019.1870 Crossref PubMed Scopus (177) Google Scholar ,2 Chastain DB Osae SP Henao-Martínez AF Franco-Paredes C Chastain JS Young HN. Racial disproportionality in COVID clinical trials. N Engl J Med. 2020; 383: e59https://doi.org/10.1056/NEJMp2021971 Crossref PubMed Scopus (74) Google Scholar Given that coronavirus disease 2019 (COVID-19) disproportionately burdens Black and Hispanic Americans, considerable attention has been given to the development of more inclusive clinical trials. 2 Chastain DB Osae SP Henao-Martínez AF Franco-Paredes C Chastain JS Young HN. Racial disproportionality in COVID clinical trials. N Engl J Med. 2020; 383: e59https://doi.org/10.1056/NEJMp2021971 Crossref PubMed Scopus (74) Google Scholar No national-level analysis of racial and ethnic differences in clinical trial recruitment, including invitation, participation, and motivation, has been performed. As new treatments are developed, such as the COVID-19 therapeutic interventions, it is timely to assess the status of racial and ethnic disparities in clinical trials in the U.S. using newly available data, which could inform recruitment strategies moving forward. Therefore, this study examines the national prevalence of clinical trial invitation, participation, and motivation by race and ethnicity.